Source-grounded facts extracted from Compass Therapeutics, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Compass Therapeutics, Inc. shareholders approved Non-binding, Advisory Vote on the Holding of the Future Advisory Votes on the Compensation of our Named Executive Officers at the 2026-06-10 meeting.
“Proposal No. 4. Non-binding, Advisory Vote on the Holding of the Future Advisory Votes on the Compensation of our Named Executive Officers. The stockholders voted, on a non-binding, advisory basis, to hold such advisory votes annually, by the votes set forth in the table below: Every Year Every Two Years Every Three Years Abstain 118,289,260 811,275 1,491,631 1,229,517”
Shareholder Votes
Compass Therapeutics, Inc. shareholders approved Non-binding, Advisory Vote on the Compensation of our Named Executive Officers at the 2026-06-10 meeting.
“Proposal No. 3. Non-binding, Advisory Vote on the Compensation of our Named Executive Officers. The stockholders voted to approve, on a non-binding, advisory basis, the compensation of the Company’s named executive officers, by the votes set forth in the table below: For Against Abstain Broker Non-votes 117,963,684 1,796,022 2,061,977 21,320,318”
Shareholder Votes
Compass Therapeutics, Inc. shareholders approved Ratification of Appointment of Independent Registered Public Accounting Firm (CohnReznick, LLP) at the 2026-06-10 meeting.
“Proposal No. 2. Ratification of Appointment of Independent Registered Public Accounting Firm. The stockholders ratified the appointment of CohnReznick, LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2026, by the votes set forth in the table below: For Against Withheld Broker Non-votes 137,896,097 181,037 5,064,867 -”
Shareholder Votes
Compass Therapeutics, Inc. shareholders approved Election of two Class III nominees for director at the 2026-06-10 meeting.
“Proposal No. 1. Election of Directors. The stockholders elected the two Class III nominees for director to serve until the Company’s 2029 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified, by the votes set forth in the table below: Name For Withheld Broker Non-votes Thomas J. Schuetz, M.D., Ph.D. 102,984,184 18,837,499 21,320,318 Richard S. Lindahl, M.B.A. 103,453,540 18,368,143 21,320,318”
Earnings Releases
Compass Therapeutics, Inc. reported the quarter ended March 31, 2026 results: revenue $195 million in cash and marketable securities.
“The Phase 1 study for CTX-10726 (PD-1 x VEGF-A bispecific antibody) has also been initiated in the post-checkpoint inhibitor setting, with initial data expected [Q4 2026]. $195 million in cash and marketable securities at Q1 2026, which is expected to fund operations into 2028. BOSTON, May 05, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX),”
Earnings Releases
Compass Therapeutics, Inc. reported year ended December 31, 2025 results: net income $66.5 million, EPS $0.42 per common share.
“Net loss for the year ended December 31, 2025, was $66.5 million or $0.42 per common share”
Thomas Schuetz was appointed as President and Chief Executive Officer at Compass Therapeutics, Inc..
“On May 28, 2024, the Board of Directors appointed Thomas Schuetz, MD, PhD, then-current President of Research and Development and Vice Chair of the Board of Directors of the Company, as President and Chief Executive Officer of the Company, and as Principal Executive Officer, Principal Financial and Principal Accounting Officer of the Company, effective immediately.”
Vered Bisker-Leib resigned as Chief Executive Officer at Compass Therapeutics, Inc..
“On May 28, 2024, Vered Bisker-Leib, PhD, MBA, resigned as Chief Executive Officer (Principal Executive Officer and Principal Financial and Accounting Officer) and resigned as a member of the Board of Directors, of Compass Therapeutics, Inc. (the “Company”) effective the same date.”
Earnings Releases
Compass Therapeutics, Inc. reported the quarter ended March 31, 2024 results: net income $10.8 million, EPS $0.08 per share of common stock.
“On May 13, 2024, Compass Therapeutics, Inc. issued a press release announcing financial results for the quarter ended March 31, 2024.”
Earnings Releases
Compass Therapeutics, Inc. reported the year ended December 31, 2023 results: net income Net loss for the year ended December 31, 2023, was $42.5 million or $0.33 per common share, EPS $0.33 per common share.
“On March 21, 2024, Compass Therapeutics, Inc. issued a press release announcing financial results for the year ended December 31, 2023.”
Thomas Schuetz changed role as President of Research and Development at Compass Therapeutics, Inc..
“Effective January 9, 2024, Thomas Schuetz, MD, PhD, the Company’s Scientific Founder and Chief Executive Officer and a member of the Board, will transition to President of Research and Development and be appointed Vice Chair of the Board.”
Vered Bisker-Leib was appointed as Chief Executive Officer at Compass Therapeutics, Inc..
“the Board of Directors (the “Board”) of Compass Therapeutics, Inc. (the “Company”) appointed Vered Bisker-Leib, PhD as Chief Executive Officer of the Company and a member the Board, each effective January 9, 2024.”
Earnings Releases
Compass Therapeutics, Inc. reported third quarter ended September 30, 2023 results: net income Net loss for the third quarter ended September 30, 2023 was $10.0 million or $0.08 per common share, EPS $0.08 per common share.
“On November 9, 2023, Compass Therapeutics, Inc. issued a press release announcing financial results for the third quarter ended September 30, 2023.”
Earnings Releases
Compass Therapeutics, Inc. reported the second quarter ended June 30, 2023 results: net income Net loss for the second quarter ended June 30, 2023 was $11.3 million or $0.09 per common share, EPS $0.09 per common share.
“On August 3, 2023, Compass Therapeutics, Inc. issued a press release announcing financial results for the second quarter ended June 30, 2023.”
Shareholder Votes
Compass Therapeutics, Inc. shareholders approved Ratification of Appointment of Independent Registered Public Accounting Firm at the 2023-06-15 meeting.
“Proposal No. 2. Ratification of Appointment of Independent Registered Public Accounting Firm. The stockholders ratified the appointment of CohnReznick, LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2023, by the votes set forth in the table below: Broker Non- For Against Abstained votes 96,574,239 130,740 24,542 0”
Shareholder Votes
Compass Therapeutics, Inc. shareholders approved Election of Class III Directors at the 2023-06-15 meeting.
“Proposal No. 1. Election of Directors. The stockholders elected the two Class III nominees for director to serve until the Company’s 2026 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified, by the votes set forth in the table below: Broker Non- Name For Withheld votes Thomas J Schuetz MD PHD 67,240,784 17,368,756 12,119,981 Richard S Lindahl MBA 84,596,658 12,882 12,119,981”
Earnings Releases
Compass Therapeutics, Inc. reported the first quarter ended March 31, 2023 results: net income $7.8 million, EPS $0.06 per share.
“Net loss for the quarter ended March 31, 2023, was $7.8 million or $0.06 per share, compared to $7.2 million or $0.07 per share for the same period in 2022.”
Richard S. Lindahl was appointed as Class III Director at Compass Therapeutics, Inc..
“On April 21, 2023, the Board of Directors (the “Board”) of Compass Therapeutics, Inc. (the “Company”) approved the appointment of a new director to its Board: Richard S. Lindahl, MBA, who is currently the executive vice president, chief financial officer, and treasurer of Emergent BioSolutions, Inc.”
David Wurzer resigned as Director at Compass Therapeutics, Inc..
“On February 20, 2023, David Wurzer, a member of the Board of Directors (the “Board”) of Compass Therapeutics, Inc. (the “Company”), notified the Company of his resignation from the Board, and all committees thereof, for personal family reasons effective immediately.”
David Wurzer was appointed as Director at Compass Therapeutics, Inc..
“On February 8, 2023, the Board of Directors (the “Board”) of Compass Therapeutics, Inc. (the “Company”) approved the appointment of a new director to its Board: David Wurzer, CPA, CFO of Enko Chem, Inc.”
Susan Kalled, PhD departed as Chief Scientific Officer at Compass Therapeutics, Inc..
“On November 29, 2022, Susan Kalled, PhD departed her position as Chief Scientific Officer of Compass Therapeutics, Inc.”
Material Agreements
Compass Therapeutics, Inc. entered into Securities Purchase Agreement with certain accredited investors valued at approximately $80 million (effective 2022-11-02).
“On November 2, 2022, Compass Therapeutics, Inc. (the “Company”) and certain accredited investors (each an “Investor” and collectively, the “Investors”) entered into a securities purchase agreement (the “Securities Purchase Agreement”) pursuant to which the Company agreed to sell and issue to the Investors in a private placement (the “Private Placement”) an aggregate of 25,000,000 shares (the “Shares”) of the Company’s common stock, par value $0.0001 per share (the “Common Stock”) at a purchase price of $3.21 per share.”
James P. Boylan was appointed as Director at Compass Therapeutics, Inc..
“On November 1, 2022, the Board appointed Mr. Boylan to join as a director of the Board, effective upon the closing of the Private Placement.”
Stephen Squinto resigned as Director at Compass Therapeutics, Inc..
“On August 17, 2022, Stephen Squinto, Ph.D., a member of the Board of Directors (the “Board”) of Compass Therapeutics, Inc. (the “Company”), notified the Company of his resignation from the Board and all committees thereof, effective August 31, 2022.”
Miranda Toledano departed as Director at Compass Therapeutics, Inc..
“On April 22, 2022, Miranda Toledano, M.B.A., a member of the Board of the Company, notified the Company that she is declining to stand for reelection to the Board at the completion of her current term, ending at the Company’s Annual Meeting of Stockholders set for May 24, 2022.”
Mary Ann Gray was appointed as Director at Compass Therapeutics, Inc..
“On April 25, 2022, the Board of Directors (the “Board”) of Compass Therapeutics, Inc. (the “Company”) appointed two new directors to its Board: Ellen Chiniara, J.D., former Chief Legal Officer of Alexion Pharmaceuticals; and Mary Ann Gray, Ph.D., President of Gray Strategic Advisors.”
Ellen Chiniara was appointed as Director at Compass Therapeutics, Inc..
“On April 25, 2022, the Board of Directors (the “Board”) of Compass Therapeutics, Inc. (the “Company”) appointed two new directors to its Board: Ellen Chiniara, J.D., former Chief Legal Officer of Alexion Pharmaceuticals; and Mary Ann Gray, Ph.D., President of Gray Strategic Advisors.”
Brett Kaplan resigned as director at Compass Therapeutics, Inc..
“On February 22, 2022, Brett Kaplan, M.D., a member of the Board of Directors (the “Board”) of Compass Therapeutics, Inc. (the “Company”), notified the Company of his resignation from the Board and all committees thereof, effective February 25, 2022.”
Julie Sunderland resigned as Director at Compass Therapeutics, Inc..
“On December 20, 2021, Julie Sunderland, a member of the Board of Directors (the “Board”) of Compass Therapeutics, Inc. (the “Company”), notified the Company of her resignation from the Board and all committees thereof, effective December 31, 2021.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.